Pharmaceutical Meeting Professionals Summit

November 3-4, 2021 | USA

The 2021 Pharma Meeting Pros Summit is back at Harrah’s Atlantic City and we can’t wait to see you again in person! If we’ve learned one thing from this pandemic, it’s that there is a very clear need for in-person events, and not everything can be replicated with a virtual experience. Let’s understand how to integrate mediums as the industry bounces back through hybrid events, and how medical meetings have forever changed as a result of this pandemic.

Spotlight

Alzheimer’s disease (AD) is the most well-known and most common type of age-related dementia. Amyloid deposition and hyperphosphorylation of tau protein are both pathological hallmarks of the AD. Using a triple-transgenic mouse model (3xTg-AD) that develops plaques and tangles in the brain similar to the human AD, we provide evidence that active full-length DNA amyloid-β peptide 1–42 (Aβ42) trimer immunization leads to the reduction of both amyloid and tau aggregation and accumulation.


OTHER PAST CONFERENCES

AMERICAN PHARMA & MEDTECH PPM CONFERENCE – WEST COAST

November 3-4, 2022 | USA

Annual Project, Program, and Portfolio Management Conference in Pharma & Biotech with a focus on New Ways of Working.

Pharma Industry & pharmaceuticals

October 3-4, 2022 | France

After a decent assembling of past drug organization gatherings, drug Conferences group merrily invites individuals from everyplace the planet to venture out to " third International meeting on Pharma Industry and drugs"

3rd World Congress on Pharmaceutical Health Science and Technology

October 24-25, 2022 | Swaziland

We are excited to welcome all attendees to our highly regarded global event, “3rd World Congress on Pharmaceutical Health Science and Technology” which will be held during October 24-25, 2022, Zurich, Switzerland.

DigIT Pharma Commercial Excellence & Digital Health

September 28-29, 2022 | Germany

Future of Pharma Business: New Pharma Business Unit Opportunities – Datengetriebene Business Itelligence und Commercial Excellence in Zeiten von DIGAs,

Spotlight

Alzheimer’s disease (AD) is the most well-known and most common type of age-related dementia. Amyloid deposition and hyperphosphorylation of tau protein are both pathological hallmarks of the AD. Using a triple-transgenic mouse model (3xTg-AD) that develops plaques and tangles in the brain similar to the human AD, we provide evidence that active full-length DNA amyloid-β peptide 1–42 (Aβ42) trimer immunization leads to the reduction of both amyloid and tau aggregation and accumulation.

resources